Skip to main content
Top
Published in: Irish Journal of Medical Science (1971 -) 3/2011

01-09-2011 | Case Report

Generalized convulsion resulted in hyperammonemia during treatment with tranexamic acid for hemoptysis

Authors: C.-S. Wang, C.-J. Yang, S.-C. Chen, H.-C. Chen, M.-S. Huang

Published in: Irish Journal of Medical Science (1971 -) | Issue 3/2011

Login to get access

Abstract

Background

Tranexamic acid is commonly used to treat various kinds of bleeding disorders. It has been shown to cause severe convulsions in animal experiments.

Aims

We report a patient who experienced a single convulsive seizure that resulted in transient hyperammonemia during treatment with tranexamic acid.

Case report

A 68-year-old man was admitted and received tranexamic acid for persistent hemoptysis. After 5 days of admission, clonic convulsions that progressed to generalized seizures were noted following the intravenous administration of the tranexamic acid. Elevated ammonia level (233 μmol/l) was found. No further seizures occurred after immediate discontinuation of the drug. No other cause of seizures was found. The ammonia level on the following day normalized even without any treatment for the hyperammonemia.

Conclusions

This case highlights that generalized convulsion is a very rare, but serious adverse effect of tranexamic acid. Generalized convulsion should be considered as a potential cause of transient hyperammonemia.
Literature
1.
go back to reference Dunn CJ, Goa KL (1999) Tranexamic acid: a review of its use in surgery and other indications. Drugs 57:1005–1032PubMedCrossRef Dunn CJ, Goa KL (1999) Tranexamic acid: a review of its use in surgery and other indications. Drugs 57:1005–1032PubMedCrossRef
2.
go back to reference Pellegrini A, Giaretta D, Chemello R, Zanotto L, Testa G (1982) Feline generalized epilepsy induced by tranexamic acid (AMCA). Epilepsia 23:35–45PubMedCrossRef Pellegrini A, Giaretta D, Chemello R, Zanotto L, Testa G (1982) Feline generalized epilepsy induced by tranexamic acid (AMCA). Epilepsia 23:35–45PubMedCrossRef
3.
go back to reference Morris SM Jr (2002) Regulation of enzymes of the urea cycle and arginine metabolism. Annu Rev Nutr 22:87–105PubMedCrossRef Morris SM Jr (2002) Regulation of enzymes of the urea cycle and arginine metabolism. Annu Rev Nutr 22:87–105PubMedCrossRef
4.
go back to reference Hawkes ND, Thomas GA, Jurewicz A, Williams OM, Hillier CE, McQueen IN, Shortland G (2001) Non-hepatic hyperammonemia: an important, potentially reversible cause of encephalopathy. Postgrad Med J 77:717–722PubMedCrossRef Hawkes ND, Thomas GA, Jurewicz A, Williams OM, Hillier CE, McQueen IN, Shortland G (2001) Non-hepatic hyperammonemia: an important, potentially reversible cause of encephalopathy. Postgrad Med J 77:717–722PubMedCrossRef
5.
go back to reference Graham TE (1994) Exercise-induced hyperammonemia: skeletal muscle ammonia metabolism and the peripheral and central effects. Adv Exp Med Biol 368:181–195PubMed Graham TE (1994) Exercise-induced hyperammonemia: skeletal muscle ammonia metabolism and the peripheral and central effects. Adv Exp Med Biol 368:181–195PubMed
6.
go back to reference Yanagawa Y, Nishi K, Sakamoto T (2008) Hyperammonemia is associated with generalized convulsion. Intern Med 47:21–23PubMedCrossRef Yanagawa Y, Nishi K, Sakamoto T (2008) Hyperammonemia is associated with generalized convulsion. Intern Med 47:21–23PubMedCrossRef
Metadata
Title
Generalized convulsion resulted in hyperammonemia during treatment with tranexamic acid for hemoptysis
Authors
C.-S. Wang
C.-J. Yang
S.-C. Chen
H.-C. Chen
M.-S. Huang
Publication date
01-09-2011
Publisher
Springer-Verlag
Published in
Irish Journal of Medical Science (1971 -) / Issue 3/2011
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-009-0453-y

Other articles of this Issue 3/2011

Irish Journal of Medical Science (1971 -) 3/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.